Editas Medicine CRISPR therapy shows robust LDL-C lowering in preclinical trials

Editas Medicine (NASDAQ:EDIT) presented compelling new data on its lead in vivo gene-editing candidate, EDIT-401, demonstrating its potential as a durable, one-time treatment for hyperlipidemia.

The findings, shared at the 2026 ASGCT and TIDES meetings, highlight the company’s shift toward "upregulation" strategies following the discontinuation of its previous ex vivo programs.

Editas Medicine reported that a single dose of EDIT-401 achieved a mean LDL-C reduction of 90% or greater in non-human primates (NHPs).

The reduction remained durable for approximately six months across dose levels ranging from 1.5 to 3 mg/kg.

Notably, the therapy achieved these results with only 10% to 40% functional editing of hepatic cells, which translated to a six-fold increase in the production of the LDLR protein responsible for clearing "bad" cholesterol.

The preclinical data also pointed to a favorable safety profile.

At the therapeutically relevant dose of 1.5 mg/kg, researchers observed no adverse clinical effects and confirmed that the CRISPR machinery was successfully targeted to the liver.

Testing showed undetectable levels of the therapy in non-target tissues, such as oocytes, addressing a key regulatory concern regarding off-target gene editing.

The update comes as Editas consolidates its financial position.

In its Q1 2026 earnings report released earlier this month, the company narrowed its net loss to $25 million, down from $76.1 million a year ago.

With $123.6 million in cash on hand, the company expects its runway to extend into the third quarter of 2027.

Editas is currently preparing to initiate a first-in-human clinical trial for patients with Heterozygous Familial Hypercholesterolemia (HeFH) later this year, with initial proof-of-concept data expected by year-end.